Why the study?
Individuals with rheumatoid arthritis face increased cardiovascular mortality from heart failure, but the role of citrullination and malondialdehyde-acetaldehyde post-translational modifications in rheumatoid arthritis-associated heart failure is not well understood.
Does fibrinogen co-modified with malondialdehyde-acetaldehyde and citrulline (FIB-MAA-CIT) promote macrophage activation and subsequent coronary endothelial cell inflammation in the context of rheumatoid arthritis-associated heart failure?
Does fibrinogen co-modified with malondialdehyde-acetaldehyde and citrulline (FIB-MAA-CIT) promote macrophage activation and subsequent coronary endothelial cell inflammation in the context of rheumatoid arthritis-associated heart failure?
This study identifies a novel mechanism in rheumatoid arthritis-associated heart failure whereby fibrinogen co-modified with citrulline and malondialdehyde-acetaldehyde activates macrophage NF-κB and p38 pathways to drive coronary endothelial cell inflammation and perivascular fibrosis.
Answers are grounded in this paper and cite their sources.
Does not support practice change in RA-HF; hypothesis-generating for modified fibrinogen in myocardial inflammation.
Individuals with rheumatoid arthritis (RA) face increased cardiovascular mortality due to heart failure (HF) complications. Post-translational modifications, such as citrullination (CIT) and malondialdehyde-acetaldehyde (MAA) adduction, are implicated in RA pathogenesis. However, their role in RA-associated HF is not well understood. This study examines the deposition of MAA and CIT in cardiac tissues of RA-HF patients and investigates how MAA and CIT adducts on fibrinogen (FIB-MAA-CIT) drive crosstalk between macrophages and endothelial cells in vitro. We demonstrated elevated MAA and CIT adducts, strong perivascular MAA-CIT co-localization, and increased perivascular collagen deposition in the myocardium of RA-HF patients compared to non-RA HF controls. Treating human coronary artery endothelial cells (HCAECs) with FIB-MAA-CIT induced upregulation of inflammatory markers including MCP-1, IL-6, ICAM-1, and VCAM-1 compared to unmodified FIB. This response was amplified when HCAECs were treated with cell culture media obtained from FIB-MAA-CIT-stimulated macrophages. FIB-MAA-CIT activation of macrophages engaged NF-κB and p38 signaling pathways and inhibition of these pathways reduced FIB-MAA-CIT-mediated macrophage cytokine secretion and subsequent HCAEC responses. In summary, our findings support a novel mechanism by which endogenously modified proteins drive macrophage-endothelial cell crosstalk, promoting myocardial inflammation. Targeting these post-translational modifications may present novel therapeutic strategies to mitigate HF in RA.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: